Treatment of patients with pancreatic endocrine tumours using a new long-acting somatostatin analogue symptomatic and peptide responses

Gut. 1985 May;26(5):438-44. doi: 10.1136/gut.26.5.438.

Abstract

Seven patients with gut and pancreatic endocrine tumours have been treated with a long acting somatostatin analogue (SMS 201-995), given as a twice daily subcutaneous injection. This produced dramatic improvement in their endocrine related symptoms, in association with a fall in circulating tumour peptides. One of these patients has now been treated for seven months with this analogue which has controlled his previously life threatening diarrhoea caused by a malignant VIP secreting tumour. He gives his own injections twice daily, and has returned to a full and active life. This is a promising agent both for acute treatment of peptide hypersecretion, and for the long term management of some patients who are unresponsive to other available therapy.

MeSH terms

  • Adult
  • Aged
  • Diarrhea / drug therapy
  • Female
  • Gastrins / blood
  • Gastrins / metabolism
  • Glucagon / blood
  • Glucagon / metabolism
  • Humans
  • Male
  • Middle Aged
  • Octreotide
  • Pancreatic Neoplasms / metabolism*
  • Paraneoplastic Endocrine Syndromes / blood
  • Paraneoplastic Endocrine Syndromes / drug therapy*
  • Peptide PHI
  • Peptides / blood
  • Peptides / metabolism*
  • Somatostatin / analogs & derivatives*
  • Somatostatin / therapeutic use
  • Vasoactive Intestinal Peptide / blood
  • Vasoactive Intestinal Peptide / metabolism

Substances

  • Gastrins
  • Peptide PHI
  • Peptides
  • Vasoactive Intestinal Peptide
  • Somatostatin
  • Glucagon
  • Octreotide